The FINANCIAL -- Berlin, September 13, 2011 – Bayer HealthCare Pharmaceuticals announced today that the company will present new data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

These presentations, including the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) data evaluating Alpharadin (radium-223 chloride) in patients with castration-resistant prostate cancer (CRPC), will highlight the potential of Bayer’s growing oncology pipeline.

“We look forward to presenting the complete Phase III Alpharadin data for the first time following the positive results from the ALSYMPCA interim analysis released earlier this year,” said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee. “These data, along with other presentations from our oncology pipeline, serve to demonstrate Bayer’s commitment to advancing the science of cancer and to developing innovative cancer therapies that can help people with cancer live longer.”

Related Stories

• New Phase 3 data for Tradjenta tablets in black or African American patients with type 2 diabetes
• Innovative public-private collaboration launches to tackle antibiotic research
• Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure